ADJUVANT TREATMENT OF FULLY RESECTED STAGE III COLON CANCER WITH FOLFOX-4 VERSUS FOLFOX-4 PLUS CETUXIMAB

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-003463-23

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary objective of the study is to assess and to compare the disease free survival curves according to treatment arm in patients with completely resected stage III colon cancer and KRAS wild-type tumor status (ITT KRAS wild-type population).


Critère d'inclusion

  • FULLY RESECTED STAGE III COLON CANCER